Immunovant To Report Financial Results For The Second Quarter Ended September 30, 2025, And Provide Business Update On Monday, November 10, 2025

2025-10-27 04:16:25

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under“News & Events” in the Investors section of the Immunovant website at The archived webcast will be available on Immunovant's website after the conference call.

About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant

Contacts:
Investors
Keyur Parekh
...

Media
Stephanie Lee
...

MENAFN27102025004107003653ID1110255394

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.